0001193125-18-343801.txt : 20190227 0001193125-18-343801.hdr.sgml : 20190227 20181206164601 ACCESSION NUMBER: 0001193125-18-343801 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20181206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GenMark Diagnostics, Inc. CENTRAL INDEX KEY: 0001487371 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 272053069 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 5964 LA PLACE COURT CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: (760) 448-4300 MAIL ADDRESS: STREET 1: 5964 LA PLACE COURT CITY: CARLSBAD STATE: CA ZIP: 92008 CORRESP 1 filename1.htm CORRESP

December 6, 2018

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549-4561

Attn: Ms. Percival

 

Re:

GenMark Diagnostics, Inc.

    

Registration Statement on Form S-3

    

File No. 333-228486

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, GenMark Diagnostics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Standard Time, on Friday, December 7, 2018, or as soon thereafter as practicable.

The Company acknowledges that:

 

  •

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing;

 

  •

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

  •

the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please contact Michael S. Kagnoff of DLA Piper LLP (US) with any questions or comments at (858) 638-6722. Thank you for your assistance with this filing.

 

Very truly yours,
GenMark Diagnostics, Inc.
By:  

/s/ Scott Mendel

Name:   Scott Mendel
Title:   Chief Financial Officer